Literature DB >> 26234679

Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.

A Sayadi1, J Jeyakani2, S H Seet1, C-L Wei2, G Bourque2, F A Bard1, N A Jenkins1, N G Copeland1, E A Bard-Chapeau1.   

Abstract

The MDS1 and ecotropic viral integration site 1 (EVI1) complex locus (MECOM) gene encodes several transcription factor variants including MDS1-EVI1, EVI1 and EVI1Δ324. Although MDS1-EVI1 has been associated with tumor-suppressing activity, EVI1 is a known oncogene in various cancers, whose expression is associated with poor patient survival. Although EVI1Δ324 is co-transcribed with EVI1, its activity in cancer cells is not fully understood. Previous reports described that unlike EVI1, EVI1Δ324 protein cannot transform fibroblasts because of its disrupted N-terminal zinc finger (ZNF) domain. To better understand EVI1Δ324 biology and function, we obtained genome-wide binding occupancies and expression data in ovarian cancer cells. We characterized its DNA-binding sites, binding motif and target genes. Comparative analyses with previous study show that EVI1 and EVI1Δ324 share similar transcriptional activities linked to their common C-terminus ZNF domain. They bind to an E-twenty-six family (ETS)-like motif, target to a large extent the same genes and cooperate with AP1 transcription factor. EVI1Δ324-occupied genes were 70.7% similar to EVI1-bound genes. More strikingly, EVI1 and EVI1Δ324 differentially expressed genes were 99.87% identical, indicating comparable transcriptional regulatory functions. Consistently with gene ontologies linked to these target genes, EVI1Δ324 expression in HeLa cells could enhance anchorage-independent growth, such as EVI1, showing that EVI1Δ324 expression also lead to pro-oncogenic effects. The main specific feature of EVI1 variant is its N-terminus ZNF domain that binds DNA through GATA-like motif. We found that most GATA-like EVI1 chromatin immunoprecipitation sequencing peaks are far from genes and are not involved in transcriptional regulation. These genomic regions were enriched in simple sequence repeats and displayed high meiotic recombination rates. Overall, our genomics analyses uncovered common and specific features of two major MECOM isoforms. Their influence on transcription and downstream cell proliferation was comparable. However, EVI1-specific GATA-like binding sites, from its N-terminus ZNF domain, associated with high recombination rates, suggesting possible additional oncogenic potential for EVI1 in modulating genomic stability.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26234679     DOI: 10.1038/onc.2015.286

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  71 in total

1.  Oogenesis in the mouse. A study of the meiotic prophase.

Authors:  K BORUM
Journal:  Exp Cell Res       Date:  1961-09       Impact factor: 3.905

2.  The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development.

Authors:  P R Hoyt; C Bartholomew; A J Davis; K Yutzey; L W Gamer; S S Potter; J N Ihle; M L Mucenski
Journal:  Mech Dev       Date:  1997-07       Impact factor: 1.882

3.  Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends.

Authors:  Metin Aytekin; Ursula Vinatzer; Monica Musteanu; Sophie Raynaud; Rotraud Wieser
Journal:  Gene       Date:  2005-08-15       Impact factor: 3.688

4.  Relationship between transcription and initiation of meiotic recombination: toward chromatin accessibility.

Authors:  A Nicolas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

Review 5.  AP-1 in mouse development and tumorigenesis.

Authors:  W Jochum; E Passegué; E F Wagner
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

6.  A comprehensive genetic map of the human genome based on 5,264 microsatellites.

Authors:  C Dib; S Fauré; C Fizames; D Samson; N Drouot; A Vignal; P Millasseau; S Marc; J Hazan; E Seboun; M Lathrop; G Gyapay; J Morissette; J Weissenbach
Journal:  Nature       Date:  1996-03-14       Impact factor: 49.962

7.  YY1 controls immunoglobulin class switch recombination and nuclear activation-induced deaminase levels.

Authors:  Kristina Zaprazna; Michael L Atchison
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

Review 8.  EVI1 and hematopoietic disorders: history and perspectives.

Authors:  Giuseppina Nucifora; Leopoldo Laricchia-Robbio; Vitalyi Senyuk
Journal:  Gene       Date:  2005-11-28       Impact factor: 3.688

9.  Postmeiotic sex chromatin in the male germline of mice.

Authors:  Satoshi H Namekawa; Peter J Park; Li-Feng Zhang; James E Shima; John R McCarrey; Michael D Griswold; Jeannie T Lee
Journal:  Curr Biol       Date:  2006-04-04       Impact factor: 10.834

10.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

View more
  5 in total

1.  EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma.

Authors:  Luis Palomero; Lubomir Bodnar; Francesca Mateo; Carmen Herranz-Ors; Roderic Espín; Mar García-Varelo; Marzena Jesiotr; Gorka Ruiz de Garibay; Oriol Casanovas; José I López; Miquel Angel Pujana
Journal:  Cancers (Basel)       Date:  2020-01-28       Impact factor: 6.639

2.  Classification of glioma based on prognostic alternative splicing.

Authors:  Yaomin Li; Zhonglu Ren; Yuping Peng; Kaishu Li; Xiran Wang; Guanglong Huang; Songtao Qi; Yawei Liu
Journal:  BMC Med Genomics       Date:  2019-11-15       Impact factor: 3.063

Review 3.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037

4.  EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.

Authors:  Roberto Paredes; Marion Schneider; Stella Pearson; Hsiang Yin Teng; James R Kelly; Andrew Pierce; Tim C P Somervaille; Anthony D Whetton; Stefan Meyer
Journal:  Mol Biol Rep       Date:  2020-09-26       Impact factor: 2.316

5.  EVI1 phosphorylation at S436 regulates interactions with CtBP1 and DNMT3A and promotes self-renewal.

Authors:  Roberto Paredes; James R Kelly; Bethany Geary; Batool Almarzouq; Marion Schneider; Stella Pearson; Prakrithi Narayanan; Andrew Williamson; Simon C Lovell; Daniel H Wiseman; John A Chadwick; Nigel J Jones; Olga Kustikova; Axel Schambach; Terence Garner; Fabio M R Amaral; Andrew Pierce; Adam Stevens; Tim C P Somervaille; Anthony D Whetton; Stefan Meyer
Journal:  Cell Death Dis       Date:  2020-10-20       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.